

Development of a Predictor for Human Brain Tumors Based on Gene Expression Values Obtained from Two Types of Microarray Technologies

Xavier Castells,^{1,7} Juan José Acebes,^{2,7} Susana Boluda,³ Àngel Moreno-Torres,^{4,7}
Jesús Pujol,^{5,7} Margarida Julià-Sapé,⁷ Ana Paula Candiota,⁷ Joaquín Ariño,⁶
Anna Barceló,⁶ and Carles Arús^{1,7}

Abstract

Development of molecular diagnostics that can reliably differentiate amongst different subtypes of brain tumors is an important unmet clinical need in postgenomics medicine and clinical oncology. A simple linear formula derived from gene expression values of four genes (*GFAP*, *PTPRZ1*, *GPM6B*, and *PRELP*) measured from cDNA microarrays ($n = 35$) have distinguished glioblastoma and meningioma cases in a previous study. We herein extend this work further and report that the above predictor formula showed its robustness when applied to Affymetrix microarray data acquired prospectively in our laboratory ($n = 80$) as well as publicly available data ($n = 98$). Importantly, *GFAP* and *GPM6B* were both retained as being significant in the predictive model upon using the Affymetrix data obtained in our laboratory, whereas the other two predictor genes were *SFRP2* and *SLC6A2*. These results collectively indicate the importance of the expression values of *GFAP* and *GPM6B* genes sampled from the two types of microarray technologies tested. The high prediction accuracy obtained in these instances demonstrates the robustness of the predictors across microarray platforms used. This result would require further validation with a larger population of meningioma and glioblastoma cases. At any rate, this study paves the way for further application of gene signatures to more stringent biopsy discrimination challenges.

Introduction

COMPATIBILITY OF GENE EXPRESSION VALUES obtained from different microarray technology platforms for a given biological condition (e.g., in cancer tissue) has been subject to intensive research and debates (Borozan et al., 2008; Liu et al., 2008). In the context of clinical oncology and predictive medicine, such a discussion concerns the clinical validity of outcomes generated from high throughput omics technologies (Sun and Yang, 2006; Wang and Chao, 2007). Gene expression microarrays produce a substantial amount of

data that must be reproducible across diverse microarray technologies and across different centers, to be of use in clinical trials and in routine diagnostic medicine (Sun and Yang, 2006; Wang and Chao, 2007).

Over the past several years, studies have demonstrated nonsignificant variation of gene expression values for a determined biological condition, across microarray experiments using various technologies (Bosotti et al., 2007; Hwang et al., 2004; Shi et al., 2006). Nonetheless, development of prediction models to discriminate between tumor types by using gene expression data from different microarray technologies does

¹Grup d'Aplicacions Biomèdiques de la RMN (GABRMN), Facultat de Biociències, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.

²Departament de Neurocirurgia, IDIBELL-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

³Institut de Neuropatologia, Servei Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

⁴Research Department, Centre Diagnòstic Pedralbes, Esplugues de Llobregat, Barcelona, Spain.

⁵Institut d'Alta Tecnologia, CRC Corporació Sanitària, Barcelona, Spain.

⁶Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.

⁷Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Cerdanyola del Vallès, Barcelona, Spain.

not seem to have been addressed. Such an issue appears to be crucial, prior to implementation in clinical trials of prediction models derived from microarray data (Sun et al., 2006; Wang et al., 2007).

In a previous work, we were able to distinguish glioblastoma multiforme (Gbm, $n = 17$) and meningothelial meningioma (Mm, $n = 18$) biopsies through a simple linear equation derived from the expression values of four genes (*GFAP*, *PTPRZ1*, *GPM6B*, and *PRELP*), obtained from single-labeling cDNA microarray experiments (Castells et al., 2009). We take now this proof-of-principle approach one step further to investigate the robustness of the predictor developed earlier. For this goal, we evaluated the formula by prediction of three datasets, for which the gene expression values were obtained from Affymetrix microarray experiments. The two first datasets (total $n = 80$) were prospectively acquired at our laboratory, whereas the last dataset corresponded to the publicly available data ($n = 98$).

In the present study, we evaluated whether the four genes identified previously from the cDNA microarray-based data were also selected when the predictor was generated from Affymetrix data acquired in our laboratory (total $n = 80$). That is, we developed a stepwise procedure on our Affymetrix dataset to select four genes that fitted an optimal predictor for Gbs and Mgs. Subsequently, we evaluated whether this predictor could discriminate Gbs and Mgs from publicly available and cDNA microarray data. In doing so, we aimed to verify whether the four genes mentioned above could be selected to discriminate glioblastomas (Gbs) and meningiomas (Mgs) when using gene expression values from another type of microarray technology.

Materials and Methods

Collection, storage and histopathology analysis of samples prospectively acquired

Collection of biopsies was carried out at different hospitals from the Barcelona metropolitan area through the European Union-funded eTUMOUR (<http://www.etumour.net>) and HealthAgents (<http://www.healthagents.net>) projects and the Spanish-funded MEDIVO2 project.

A total of 77 biopsies were collected from the *Hospital Universitari de Bellvitge* (L'Hospitalet de Llobregat), 2 biopsies from the *Hospital Universitari Germans Trias i Pujol* (Badalona), and 1 biopsy from the *Hospital Sant Joan de Déu* (Esplugues de Llobregat). Among the 80 biopsies included in this study, 49 were glioblastomas [Gb(s), including 1 gliosarcoma] and 31 were meningiomas [Mg(s), including 22 of meningothelial subtype, 3 of fibrous subtype, 3 of psammomatous subtype, and 3 transitional meningiomas]. The full study protocol was approved by the local Ethics Committees and informed consent was obtained from all patients.

An aliquot of tumor was snap frozen in liquid nitrogen until RNA isolation. Another aliquot was fixed in 4% buffered formalin and embedded in paraffin. For routine histological examination 4 μ m-thick sections were stained with hematoxylin and eosin (HE). Both, the WHO 2000 and 2007 Nervous System Classification criteria (Kleihues and Cavenee, 2000; Louis et al., 2007) were used for diagnosis, because biopsies were collected from 2004 until 2008.

RNA isolation

Total RNA from frozen biopsies stored in liquid nitrogen was isolated following the procedure indicated by the manufacturer using the *mirVana* RNA isolation kit (Ambion-Applied Biosystems, Austin, TX, USA). RNA was characterized using a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Absence of protein contamination was monitored by the 260 nm/280 nm ratio of absorbance, and samples with a ratio ranging between 1.6 and 2.0 were accepted for further processing, as agreed in the consensus protocols for data acquisition in the eTUMOUR project. Integrity of the RNA was assessed by using the capillary electrophoretic system 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). Only samples producing a 28S/18S ratio equal or higher than 1.2 or an RNA integrity number (RIN) number equal or higher than 6 were used for further analysis.

Labeling and hybridization onto HG-U133 plus 2.0 Affymetrix microchips

The procedure described in this section was performed at the Affymetrix core facility of the *Institut de Recerca de la Vall d'Hebron* (Barcelona). Labeling was performed using the One-Cycle Target Labeling and Control Reagents kit (Affymetrix, Santa Clara, CA, USA). The starting material for the labeling protocol ranged from 0.3 to 5 μ g of total RNA and the resulting labeled cRNAs were hybridized onto the HG-U133 plus 2.0 GeneChip. Fluorescence images were obtained by scanning the microchips with the software provided with the GeneChip Scanner 3000.

Publicly available data

The raw expression data of 67 glioblastomas (GDS1976) and 31 meningiomas (GSE9438) were downloaded from the Gene Expression Omnibus (GEO) repository (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=gds>). The expression profile for glioblastomas (Gb) had been obtained from the HG-U133 A and B Affymetrix microchips. In contrast, the expression profile for meningiomas (Mgs) had been obtained from the HG-U133 plus 2.0 Affymetrix microchip.

Normalization and pattern recognition methods

Predictor from cDNA microarray data and validation on Affymetrix data. Background correction and normalization of Affymetrix data was performed using the robust multi-array average (RMA) method available in the *affy* package at the Bioconductor repository (www.bioconductor.org). As eTUMOUR has been a prospective project, the 80 cases used in this work were available in two batches. First, 32 Gbs and 12 Mgs (UAB1 dataset) and second, 17 Gbs and 19 Mgs (UAB2 dataset) became available. Each batch was separately normalized. Also, the two types of Affymetrix microchips from publicly available data were separately normalized using RMA. This was a must, because the number of probesets in each microchip is different. As described in our previous work (Castells et al., 2009), cDNA microarray data was normalized using the *average reference loess* (Edwards, 2003).

On the other hand, the gene expression values of the four discriminant genes composing the prediction formula (Eq. 1)

derived from cDNA microarray data were used to compute the discriminant scores in Affymetrix datasets as described in our previous work (Castells et al., 2009).

$$DSC = -0.394 * GFAP - 0.397 * PTPRZ1 - 0.397 * GPM6B + 0.365 * PRELP \quad (1)$$

Predictor from Affymetrix data acquired in our laboratory and validation on publicly available Affymetrix and cDNA microarray data. We normalized cDNA microarray and publicly available Affymetrix data as described in the previous subsection. In contrast, datasets UAB1 and UAB2 were normalized together using the RMA method, because both datasets were used to develop a predictor for Gbs and Mgs. The use of a dataset composed of 80 cases (UAB dataset) could provide a better estimation of the prediction accuracy in the training. The development of a predictor from datasets UAB1 and UAB2 consisted in randomly splitting the whole dataset (80 cases) in two-thirds for training and one-third for test. We maintained the frequency of each tumor type for both training and test sets and performed 200 times the random splitting. At each iteration, only training data was used to assess the statistical difference of each probeset between Gbs and Mgs. We only used those 12,145 probesets that represented genes present in the cDNA microarray (CNIO *Oncochip*, ArrayExpress acc. no. A-MEXP-261). We computed *p*-values for the probesets considered using the rank-based Wilcoxon test. These *p*-values were corrected to reduce the false discovery rate and we obtained the so-called *q*-values (Storey and Tibshirni, 2003). Among probesets with *q*-value lower than 0.05, the four probesets with highest absolute value of the difference of fluorescence intensity between Gbs and Mgs $\{abs[mean(Gbs)-mean(Mgs)]\}$ were selected to fit a predictor based on linear discriminant analysis (LDA). We used the LDA algorithm to generate the predictors, because in a preliminary yet unpublished work of our laboratory we tested

various algorithms (dLDA, k-nearest neighbor, support vector machine, and random Forest) for prediction of four types of human brain tumors (meningioma, glioblastoma, anaplastic glioma, and low grade glioma). LDA was the one that provided the highest accuracy in all pairwise comparisons. The LDA predictor was used to predict those cases left apart for test purposes.

The four genes that were most frequently selected across the 200 iterations were used to generate an LDA predictor using the whole dataset (*n* = 80).

Results

Validation of the predictor obtained from cDNA microarray data on Affymetrix data

We evaluated the Affymetrix probesets that correspond to the four genes described (*GFAP*, *PTPRZ1*, *GPM6B*, and *PRELP*). The *GFAP*, *PTPRZ1*, *GPM6B*, and *PRELP* genes are represented in the HG-U133 plus 2.0 microchip by 3, 1, 6, and 4 probesets, respectively. We selected the probeset for which the accession number and/or RefSeq number coincided with the one present in the annotation file of the cDNA microarray (CNIO *Oncochip*). We found coincidence for probeset "203540_at" of *GFAP* and "204223_at" of *PRELP*. In contrast, there was not a clear correspondence for *GPM6B* between the accession numbers provided by Affymetrix and the ones provided by the *Oncochip*'s manufacturers. For this reason, we selected the probeset of *GPM6B* for which we could find a known protein using the accession number provided by Affymetrix. As a result, we selected the "203540_at" (*GFAP*), "204469_at" (*PTPRZ1*), "209170_s_at" (*GPM6B*), and "204223_at" (*PRELP*) probesets (see Table 1).

From the 80 locally accrued cases and hybridized onto Affymetrix microchips, a subset composed of 44 samples (32 Gbs and 12 Mgs) was analyzed first [Fig. 1A]. As the prediction formula (Eq. 1) had been derived from cDNA microarray data (Castells et al., 2009), this first subset study was

TABLE 1. AFFYMETRIX PROBESETS REPRESENTING THE 4 GENES OF THE PREDICTION GBM/MM FORMULA (EQS. 1 AND 2)

Accession number	Probeset Affymetrix	Gene symbol	Locus link	UniGene	Gb/Mg ratio			Sequence mRNA length (bp)	Sequence protein length (aa)
					Affymetrix eTUMOUR UAB1	Affymetrix eTUMOUR UAB2	Affymetrix Pubmed		
NM_002055	203540_at	<i>GFAP</i>	2670	Hs.514227	40.12	327.78	37.65	3081	432
AL133013	229259_at	<i>GFAP</i>	2670	Hs.514227	51.66	46.31	27.00	3279	438
NM_002851	204469_at	<i>PTPRZ1</i>	5803	Hs.489824	156.52	544.20	125.81	8169	2,314
AI419030	209167_at	<i>GPM6B</i>	2824	Hs.495710	58.90	57.53	28.19	458	—
AW148844	209168_at	<i>GPM6B</i>	2824	Hs.495710	74.86	46.35	36.59	415	—
N63576	209169_at	<i>GPM6B</i>	2824	Hs.495710	72.07	60.04	25.41	396	—
AF016004	209170_s_at	<i>GPM6B</i>	2824	Hs.495710	68.16	53.63	23.93	1642	265
NM_002725	204223_at	<i>PRELP</i>	5549	Hs.632481	0.084	0.069	0.096	5833	382
AA573140	228224_at	<i>PRELP</i>	5549	Hs.632481	0.17	0.14	0.24	470	—
U41344	37022_at	<i>PRELP</i>	5549	Hs.632481	0.52	0.45	0.52	924	382

Biological information about the probesets representing the four genes (*GFAP*, *PTPRZ1*, *GPM6B*, and *PRELP*) selected to compute the Gbm/Mm formula is depicted. From left to right, the accession number, the Affymetrix probeset, the gene symbol, the locus link, and the unigene identifiers are given. The next three columns are the Gb/Mg expression ratio for each Affymetrix dataset. Finally, the length of the mRNA sequence that each probeset represents and the length of the corresponding protein are shown. A dash indicates that the protein sequence is unknown.




FIG. 1. Prediction of Affymetrix-based gene profile for Gbs and Mgs. **(A)** Robustness of the developed formula (Eq. 1) using cDNA microarrays and based on four genes (*GFAP*, *PTPRZ1*, *GPM6B*, and *PRELP*), was assessed by prediction of 32 Gb and 12 Mg cases, for which the gene profile was obtained from Affymetrix microchips. Solid symbols denote Gbs and empty symbols indicate Mgs. Round symbols corresponds to cDNA microarrays-hybridized cases (17 Gbms and 18 Mms) used in reference (Castells, 2009). Squares indicate the first batch of Affymetrix microchips-hybridized samples (32 Gbs and 12 Mgs, UAB1 dataset). **(B)** This figure displays discriminant values obtained from Equation 2. A higher interclass distance and lower intraclass distance than in **A** can be seen. The additional Affymetrix cases (17 Gbs and 19 Mgs, UAB2 dataset) are represented by triangles and the publicly available data (67 Gbs and 31 Mgs, Pubmed dataset) symbolized by rhombi. Along the y axis, the discriminant score (DSC) of each sample is depicted, whereas samples are arbitrarily distributed along the x-axis.

used to fine tune the prediction formula for gene expression values obtained from Affymetrix microarrays. Accordingly, the expression values of the four mentioned genes from the first batch of Affymetrix data (32 Gbs and 12 Mgs) were used to derive an optimized LDA formula. As a result, we obtained a predictor (Eq. 2) that maximized the interclass distance and minimized the intraclass distance (see Fig. 1B):

$$\text{DSC} = 0.0785 * \text{GFAP} + 0.620 * \text{PTPRZ1} + 0.670 * \text{GPM6B} + 0.660 * \text{PRELP} \quad (2)$$

The cutoff point at 0 enables prediction between the two tumor types, being Gb and Mg for negative and positive values, respectively. This formula was derived from the whole dataset UAB1. To provide an estimation of the prediction accuracy of the formula, we performed a leave-one-out crossvalidation (Dupuy and Simon, 2007). An apparent 100% of prediction accuracy for a new sample was estimated from dataset UAB1.

Furthermore, to obtain the discriminant score (DSC) for a new sample, the *GFAP*, *PTPRZ1*, *GPM6B*, and *PRELP* values

must be standardized using the mean (**C**) and the variance (**S**) estimated for each probeset from the dataset UAB1:

$$\begin{aligned} C(\text{GFAP}, \text{PTPRZ1}, \text{GPM6B}, \text{PRELP}) \\ = (8.904749, 7.786328, 9.182813, 7.596874) \end{aligned}$$

$$\begin{aligned} S(\text{GFAP}, \text{PTPRZ1}, \text{GPM6B}, \text{PRELP}) \\ = (3.702787, 3.728053, 3.094604, 1.735198) \end{aligned}$$

Standardization was performed for each probeset by combining the mean, the variance, and the fluorescence value of each probeset normalized (**n**) using RMA:

$$\begin{aligned} \text{GFAP} &= (\mathbf{n}(\text{GFAP}) - C(\text{GFAP}))/S(\text{GFAP}) \\ \text{PRELP} &= (\mathbf{n}(\text{PRELP}) - C(\text{PRELP}))/S(\text{PRELP}) \end{aligned}$$

Such a computation increased the interclass distance and reduced the intraclass distance of both the initial UAB1 and the second UAB2 dataset composed of 17 Gbs and 19 Mgs (see Fig. 1B). Furthermore, the adjusted formula fully predicted the class of the Pubmed dataset composed of 67 Gbs and 31 Mgs, whose gene expression profile was publicly available at the GEO data repository (see Fig. 1B). As a remark, the gene expression profile of the 31 Mgs from the GEO repository (GSE9438) was obtained using the HG-U133 plus 2.0 Affymetrix microchip. In contrast, the gene profiles of the 67 Gbs in dataset GDS1976 were obtained using the HG-U133 A and B Affymetrix microchips. At any rate, a 100% of correct prediction was obtained for all samples tested.

Development of a predictor based on Affymetrix data acquired in our laboratory and validation on publicly available Affymetrix and cDNA microarray data

The development of a predictor from the UAB dataset ($n=80$) was based in an iterative process. Cases were split 200 times into a group of training (two-thirds of cases) and a group of test (one-third of cases). Statistical difference between Gbs and Mgs was only computed in training samples. At each iteration, we computed the difference between the average of fluorescence intensity between Gbs and Mgs for each probeset. As the discrimination capacity would arise either from a positive or a negative difference, we computed the absolute value of such differences $\{\text{abs}[\text{mean}(\text{Gbs}) - \text{mean}(\text{Mgs})]\}$. To fit the LDA predictor, we selected the four probesets that displayed the highest absolute difference and a q -value lower than 0.05. We estimated the prediction accuracy as the average obtained from the test samples across the 200 iterations. We obtained 99.8% prediction accuracy, 99.75% sensitivity, 99.84% specificity, and an interval of prediction from 90–100%. Across the 200 iterations, only seven different probesets were selected to fit the LDA predictors. Interestingly, the third and fourth most selected probesets corresponded to *GFAP* and *GPM6B* (see Supplementary Table 1). Moreover, the first and second most selected probesets corresponded to the same gene: *SFRP2*. We selected to compute a final LDA predictor the four most selected probesets that corresponded to a unique gene: *SFRP2*, *GFAP*, *GPM6B*, and *SLC6A2*. That is, we only used for the LDA predictor the most selected probeset of *SFRP2* across training. We were forced to do this selection because

we wanted to use this formula for cDNA microarray data. As in cDNA microarray data there is only a unique sequence represented for each gene, selection of more than one probeset from the same gene was meaningless to fit the predictor. As a result, we generated an LDA predictor (Eq. 3) using the expression values of the four probesets mentioned above (see Table 2) and those cases from dataset UAB1:

$$DSC = -0.0070 * SFRP2 + 0.0633 * GFAP + 1.129 * GPM6B - 0.541 * SLC6A2 \quad (3)$$

As described in the previous subsection, the cutoff point at 0 enables prediction between the two tumor types, being Gb and Mg for negative and positive values, respectively.

As it can be seen in Figure 2A, a full discrimination between Gbs and Mgs was obtained for datasets UAB1, UAB2, and publicly available data. However, some Gbs from publicly available data appeared close to the cutoff point (DSC = 0). For this reason, we generated a new LDA predictor with the same probesets but using expression values of those cases from dataset UAB2.

This new LDA predictor (Eq. 4) produced a higher separation between Gbs and Mgs than the one from Equation 3 (see Fig. 2B):

$$DSC = -0.437 * SFRP2 + 0.437 * GFAP + 0.262 * GPM6B - 0.486 * SLC6A2 \quad (4)$$

To obtain the discriminant score (DSC) for a new sample, the *SFRP2*, *GFAP*, *GPM6B*, and *SLC6A2* values must be standardized using the mean (C) and the variance (S) estimated for each probeset from the dataset UAB2:

$$C(SFRP2, GFAP, GPM6B, SLC6A2) = (9.381613, 8.166541, 8.841530, 9.977249)$$

$$S(SFRP2, GFAP, GPM6B, SLC6A2) = (3.937627, 4.485970, 3.852770, 2.598600)$$

Standardization was performed for each probeset by combining the mean, the variance and the fluorescence value of each probeset normalized (n) using RMA:




FIG. 2. Predictor for Gbs and Mgs based on Affymetrix data. (A) Robustness of the developed formula (Eq. 3) using Affymetrix data from the dataset UAB1 (32 Gbs and 12 Mgs, UAB1 dataset) and based on four genes (*SFRP2*, *GFAP*, *GPM6B*, and *SLC6A2*), was assessed by prediction of the Affymetrix dataset UAB2 (17 Gb and 19 Mg cases) and publicly available data (67 Gbs and 31 Mgs, Pubmed dataset). Solid symbols denote Gbs and empty symbols indicate Mgs. Squares indicate the first batch of Affymetrix microchips-hybridized samples. The second batch of Affymetrix cases acquired in our laboratory (UAB2 dataset) is represented by triangles and the publicly available (Pubmed dataset) data symbolized by rhombi. (B) This figure displays discriminant values obtained from Equation 4. A higher interclass distance than in A can be seen. Round symbols corresponds to cDNA microarrays-hybridized cases (17 Gbms and 18 Mms) used in reference (Castells, 2009). Along the y-axis, the discriminant score (DSC) of each sample is depicted, whereas samples are arbitrarily distributed along the x axis.

$$SFRP2 = (n(SFRP2) - C(SFRP2))/S(SFRP2)$$

$$SLC6A2 = (n(SLC6A2) - C(SLC6A2))/S(SLC6A2)$$

To provide an estimation of the prediction accuracy of the formula, we performed a leave-one-out crossvalidation

TABLE 2. AFFYMETRIX PROBESETS REPRESENTING THE FOUR GENES OF THE PREDICTION Gb/Mg FORMULA (EQS. 3 AND 4)

Accession number	Probeset Affymetrix	Gene symbol	Locus link	UniGene	Gb/Mg ratio			cDNA UAB	Sequence mRNA length (bp)	Sequence protein length (aa)
					Affymetrix eTUMOUR UAB1	Affymetrix eTUMOUR UAB2	Affymetrix Pubmed			
AF311912	223122_s_at	<i>SFRP2</i>	6423	Hs.481022	0.032	0.011	0.026	0.212	1,988	295
NM_002055	203540_at	<i>GFAP</i>	2670	Hs.514227	42.90	165.89	37.65	412.52	3,081	432
AI419030	209167_at	<i>GPM6B</i>	2824	Hs.495710	62.74	49.69	28.19	132.77	458	—
AI025519	205097_at	<i>SLC26A2</i>	1836	Hs.302738	0.045	0.038	0.024	0.013	977	—

Biological information about the probesets representing the four genes (*SFRP2*, *GFAP*, *GPM6B*, and *SLC6A2*) selected to compute the Gb/Mg formula is depicted. From left to right, the accession number, the Affymetrix probeset, the gene symbol, the locus link, and the unigene identifiers are given. The next three columns are the Gb/Mg expression ratio for each Affymetrix dataset. Finally, the length of the mRNA sequence that each probeset represents and the length of the corresponding protein are shown. A dash indicates that the protein sequence is unknown.

(Dupuy and Simon, 2007). An apparent 100% of prediction accuracy for a new sample was estimated from dataset UAB2.

Discussion

Reproducibility of gene expression values from microarray data for a given biological condition across technologies or platforms is a crucial consideration prior to evaluating putative predictors of cancer subtypes in a clinical investigation (Sun and Yang, 2006; Wang and Chao, 2007). Previous work has demonstrated the ability of gene signatures based on microarray data to delineate molecular types of human brain tumors (Lee et al., 2008; Nutt et al., 2003; Phillips et al., 2006). However, none of them has proposed a mathematical formula and tested it across different microarray platforms.

We demonstrate in this work that a prediction formula derived from single-labeling cDNA microarray (CNIO *Oncochip*) data is valid after minor tuning (see Eq. 2) to predict diagnosis of cases, for which the gene expression profile is obtained from two types of Affymetrix microchips. To verify the robustness of the four selected genes from cDNA microarray data, we evaluated whether these genes were also selected from Affymetrix data to predict Gbs and Mgs. For this purpose, we performed a stepwise procedure on the Affymetrix dataset UAB ($n=80$). This was based on splitting samples in two-thirds for training and one-third for test. We performed 200 iterations and selected in each iteration the four probe sets with highest absolute value of the difference between Gb and Mg cases from the training set $\{abs[\text{mean}(\text{Gbs})-\text{mean}(\text{Mgs})]\}$. As it can be seen in Supplementary Table 1 and in Table 2, *SFRP2*, *GFAP*, *GPM6B*, and *SLC6A2* were the most selected genes for classification.

This result corroborates the robustness of the genes selected from cDNA microarray data. That is, *GFAP* and *GPM6B* were selected when Affymetrix data was used to develop the predictor for Gbs and Mgs. Naturally, it may be hypothesized that complete robustness would have been corroborated if the same four genes had been selected. In our opinion, this would have been unrealistic. We expected that *GFAP* was selected, because it is only expressed in glial cells. In fact, the same probe set of *GFAP* that we chose when validating the formula obtained from cDNA microarrays was selected. In contrast, two different probesets of *GPM6B* ("209167_at" and "209170_s_at") were selected across the 200 iterations (see Supplementary Table 1) and the most selected one ("209167_at") was not the same as the one we selected for the cDNA microarray formula ("209170_s_at"). Taking all this evidence into account, our interpretation is that half of genes that were selected to fit a predictor using cDNA microarray data have also been selected when using Affymetrix data. This may suggest that either the two other genes (*PTPRZ1* and *PRELP*) are not so relevant for prediction or there is a difference in the specificity and/or sensitivity between HG-U133 plus 2.0 Affymetrix microchip and the CNIO *Oncochip*. Considering that the manufacture of these two types of microarrays is very different and that there is a large amount of genes represented in gene expression microarrays, both possibilities are plausible.

To our knowledge, this is the first time that a prediction formula is proposed to predict the diagnosis of two human

brain tumors through an objective method, which is based on gene expression microarray values of two sets of genes: *GFAP*, *PTPRZ1*, *GPM6B*, and *PRELP*; and *SFRP2*, *GFAP*, *GPM6B*, and *SLC6A2*. Furthermore, these two sets of genes can predict Gbs and Mgs, from which the gene expression profile has been obtained from three different types of microarray (CNIO *Oncochip*, HG-U133 plus 2.0 and HG-U133 A-B). A 100% of prediction accuracy can be obtained using both sets of genes (Eqs. 2 and 4, and Figs. 1B and 2B) when tested in an independent dataset. Nonetheless, it may be more realistic to state that the expected accuracy in a possible future prospective study should be some value within the interval obtained in the training process of the predictor. That is, 90–100% when the predictor is developed from Affymetrix data (see the Results section), and 70–100% when the predictor is developed from cDNA microarray data, as described in our previous work (Castells et al., 2009). Those confidence intervals are due to the still limited number of cases investigated. Accordingly, our work provides proof-of-principle to allow future implementation in the clinical routine of objective methods to identify cancer types based on gene signatures derived from microarray data. This issue has been addressed during the preceding years using microarray and other types of data (Khan et al., 2008; Tate et al., 2006; Tonini and Pistoia, 2006; Yang et al., 2009), but it remains a matter still in discussion (Sotiriou and Piccart, 2007).

Furthermore, an interesting feature of our predictors relies on the discriminative capacity of the two sets of genes selected. Both sets of genes show a high fold change across all datasets tested. In the case of cDNA microarray data, the biological meaning of the four genes selected is more coherent than when selecting genes from Affymetrix data. As expected, *GFAP* is the main contributor to the capacity of discrimination of Equation 2 (see Table 1), because it is specifically expressed in glial cells (Baba et al., 1997; Eng et al., 2000). Although not specifically expressed in Gbs, *PTPRZ1* shows a high expression in Gbs compared to Mgs (see Table 1). In addition, suppression of the activity of the *PTPRZ1* protein with antibodies has been proposed as a therapy for Gbs (Muller et al., 2004). Similarly, the high expression of *GPM6B* and *PRELP* in Gb and Mg, respectively, can be detected along all datasets (see Table 1). Interestingly, the *PRELP* gene is a member of the family of the small leucine rich proteoglycans (SLRPs). Other members of SLRPs (*FMOD*, *OMD*, *BGN*, and *OGN*) were found overexpressed in Mgs when using cDNA microarray data (Castells et al., 2009). This allows identifying the apparent involvement of this gene family in the biology of Mgs, as described in our previous work (Castells et al., 2009).

Moreover, *GFAP* was the second gene most frequently selected when using Affymetrix data to develop the predictor for Gbs and Mgs. The gene that encodes the secreted frizzled-related protein 2 (*SFRP2*) was the most selected across training. In our opinion, this suggests that the specificity of the *GFAP* probesets represented in Affymetrix microchips may be lower compared to the full cDNA sequence of *GFAP*, which is spotted onto the CNIO *Oncochip*. Interestingly, *GPM6B* was the third most selected gene in Affymetrix data. This was the same position in which was ranked when using cDNA microarray data. This indicates that the expression level of this gene is stable across these two types of microarray technologies and corroborates its involvement in the biology of glioblastomas. The solute

carrier family member 6A2 (*SLC6A2*) encodes a transporter of noradrenaline.

In Supplementary Table 1, we describe all probesets that were selected across the 200 iterations when developing the predictor using Affymetrix data. That is, we annotated at each iteration the 100 probesets with the highest absolute value of the difference of fluorescence intensity between Gbs and Mgs $\{abs[\text{mean}(\text{Gbs})-\text{mean}(\text{Mgs})]\}$ and all probesets selected are described in Supplementary Table 1. Interestingly, *PTPRZ1* displayed on average the 16th highest absolute value of the difference of fluorescence intensity between Gbs and Mgs. This would confirm the high expression value of this gene in glioblastoma, although not high enough to be ranked among the four genes with highest difference. In contrast, *PRELP* was not selected, but osteoglycin (*OGN*), another member of the SLRPs family, was selected. This may confirm the apparent relevance of SLRPs members in the biology of meningiomas that we detected in cDNA microarray data.

Taken together, our study paves the way for further application of gene signatures obtained with different microarray platforms to automate more stringent human brain tumor discrimination challenges.

Conclusions

Our study provides support for the idea that objective prediction of certain types of human brain tumors using gene signatures obtained from three types of microarrays is feasible. This result would require further validation with a larger population of meningioma and glioblastoma cases. At any rate, our findings pave the way for further application of gene signatures obtained with different microarray platforms to predict more stringent human brain tumor discrimination challenges.

Acknowledgments

We thank Dr. Montserrat Robles, Dr. Juan Miguel García-Gómez, and Alfredo Tomás Navarro-Muñoz for their help in the development of the optimized cDNA data-based formula to predict tumor cases, whose gene profile was obtained from Affymetrix experiments. We thank Dr. Jaume Capellades from the Hospital Universitari Germans Trias i Pujol (Badalona) and Dr. Antoni Capdevila from the Hospital Sant Joan de Déu (Esplugues de Llobregat) for their collaboration with collection of biopsies. We also thank Dr. Fátima Núñez, Dr. Ricardo Gonzalo, and Dr. Francisca Gallego from the Affymetrix core facility of the UCTS Servei de Genòmica de l'Institut de Recerca de la Vall d'Hebron. This work was funded by the EU-funded grants eTUMOUR (FP6-2002-LIFESCIHEALTH 503094), Health Agents (IST-2004-27214) and the Spanish grant MEDIVO2 (SAF 2005-03650). CIBER-BNN is an initiative of "Instituto de Salud Carlos III" (ISCIII, Spain).

Author Disclosure Statement

The authors declare that no conflicting financial interests exist.

References

Baba, H., Nakahira, K., Morita, N., Tanaka, F., Akita, H., and Ikenaka, K. (1997). GFAP gene expression during development of astrocyte. *Dev Neurosci* 19, 49–57.

Borozan, I., Chen, L., Paepfer, B., Heathcote, J.E., Edwards, A.M., Katze, M., et al. (2008). MAID: an effect size based model for microarray data integration across laboratories and platforms. *BMC Bioinformatics* 9, 305.

Bosotti, R., Locatelli, G., Healy, S., Scacheri, E., Sartori, L., Mercurio, C., et al. (2007). Cross platform microarray analysis for robust identification of differentially expressed genes. *BMC Bioinformatics* 8(Suppl 1), S5.

Castells, X., García-Gómez, J.M., Navarro, A.T., Acebes, J.J., Godino, O., Boluda, S., et al. (2009). Automated brain tumor biopsy prediction using single-labeling cDNA microarrays-based gene expression profiling. *Diag Mol Pathol* 18, 206–278.

Dupuy, A., and Simon, R.M. (2007). Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. *J Natl Cancer Inst* 99, 147–157.

Edwards, D. (2003). Non-linear normalization and background correction in one-channel cDNA microarray studies. *Bioinformatics* 19, 825–833.

Eng, L.F., Ghirmikar, R.S., and Lee, Y.L. (20002). Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). *Neurochem Res* 25, 1439–1451.

Hwang, K.B., Kong, S.W., Greenberg, S.A., and Park, P.J. (2004). Combining gene expression data from different generations of oligonucleotide arrays. *BMC Bioinformatics* 5, 159.

Khan, M.U., Choi, J.P., Shin, H., and Kim, M. (2008). Predicting breast cancer survivability using fuzzy decision trees for personalized healthcare. *Proc Annu Int Conf IEEE Eng Med Biol Soc* 5148–5151.

Kleihues, P., and Cavenee, W.K. (2000). *Pathology and Genetics of Tumours of the Nervous System*, 3rd ed. (IARC, Lyon).

Lee, Y., Scheck, A.C., Cloughesy, T.F., Lai, A., Dong, J., Farooqi, H.K., et al. (2008). Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. *BMC Med Genomics*, 1–52.

Liu, H.C., Chen, C.Y., Liu, Y.T., Chu, C.B., Liang, D.C., Shih, L.Y., et al. (2008). Cross-generation and cross-laboratory predictions of Affymetrix microarrays by rank-based methods. *J Biomed Informatics* 41, 570–579.

Louis, D.N., Ohgaki, H., Wiestler, O.D., and Cavenee, W.K. (2007). *WHO Classification of Tumours of the Central Nervous System*, 4th ed. (IARC, Lyon).

Muller, S., Lamszus, K., Nikolic, K., and Westphal, M. (2004). Receptor protein tyrosine phosphatase zeta as a therapeutic target for glioblastoma therapy. *Expert Opin Ther Targets* 8, 211–220.

Nutt, C.L., Mani, D.R., Betensky, R.A., Tamayo, P., Cairncross, J.G., Ladd, C., et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. *Cancer Res* 63, 1062–1067.

Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell* 9, 157–173.

Shi, L., Reid, L.H., Jones, W.D., Shippy, R., Warrington, J.A., Baker, S.C., et al. (2006). The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. *Nature Biotechnol* 24, 1151–1161.

Sotiriou, C., and Piccart, M.J. (2007). Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? *Nat Rev Cancer* 7, 545–553.

- Storey, J.D., and Tibshinni, R. (2003). Statistical significance for genomewide studies. *Proc Natl Acad Sci USA* 100, 9440–9445.
- Sun, Z., and Yang, P. Gene expression profiling on lung cancer outcome prediction: present clinical value and future premise. (2006). *Cancer Epidemiol Biomarkers Prev* 15, 2063–2068.
- Tate, A.R., Underwood, J., Acosta, D.M., Julià-Sapé, M., Majós, C., Moreno-Torres, A. et al. (2006). Development of a decision support system for diagnosis and grading of brain tumours using *in vivo* magnetic resonance single voxel spectra. *NMR Biomed* 19, 411–434.
- Tonini, G.P., and Pistoia, V. (2006). Molecularly guided therapy of neuroblastoma: a review of different approaches. *Curr Pharm Des* 12, 2303–2317.
- Wang, T.H., and Chao, A. (2007). Microarray analysis of gene expression of cancer to guide the use of chemotherapeutics. *Taiwan J Obstet Gynecol* 46, 222–229.
- Yang, L., Tuzel, O., Chen, W., Meer, P., Salaru, G., Goodell, L., et al. (2009). PathMiner: a Web-based tool for computer-assisted diagnostics in pathology and Foran D. *IEEE Trans Inform Technol Biomed* 13, 291–299.

Address correspondence to:

Professor Carles Arús

Grup d'Aplicacions Biomèdiques de la RMN (GABRMN)

Facultat de Biociències

Universitat Autònoma de Barcelona

08193 Cerdanyola del Vallès

Barcelona, Spain

E-mail: carles.arus@uab.cat